Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Total Current Liabilities (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Total Current Liabilities for 15 consecutive years, with $118.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 3.38% to $118.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $118.7 million, a 3.38% increase, with the full-year FY2024 number at $139.6 million, up 17.48% from a year prior.
  • Total Current Liabilities was $118.7 million for Q3 2025 at Usana Health Sciences, down from $121.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $168.1 million in Q1 2021 to a low of $103.9 million in Q2 2024.
  • A 5-year average of $133.8 million and a median of $131.9 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: rose 23.49% in 2021, then dropped 20.33% in 2022.
  • Usana Health Sciences' Total Current Liabilities stood at $158.0 million in 2021, then dropped by 8.95% to $143.8 million in 2022, then dropped by 17.37% to $118.8 million in 2023, then increased by 17.48% to $139.6 million in 2024, then dropped by 15.01% to $118.7 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Total Current Liabilities are $118.7 million (Q3 2025), $121.6 million (Q2 2025), and $137.4 million (Q1 2025).